Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

Trial Profile

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; LAG 525 (Primary) ; Spartalizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PLATforM
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2019 Planned primary completion date changed from 9 Sep 2020 to 29 Jun 2020.
    • 13 Dec 2018 Planned End Date changed from 29 Mar 2021 to 28 Mar 2022.
    • 26 Nov 2018 Planned End Date changed from 8 Sep 2021 to 29 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top